September 10th, 2013
Have We Solved The Problem of Ghostwriting?
Harlan M. Krumholz, MD, SM
Several years ago, in the midst of the Vioxx litigation, I became aware of the practice of ghostwriting throughout academic medicine. In general, marketing arms of pharmaceutical companies wanted to seed the peer-reviewed journals with articles published by academics. They would identify an academic and provide him or her drafts of the article. Sometimes they […]
NEJM Journal Watch — Recent Cardiology Articles- More Data Support Semaglutide for Obesity-Related HFpEF, Regardless of Diabetes Diagnosis
- A Novel Agent Fails to Improve Outcomes in Diabetic Cardiomyopathy
- Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?